Tradestie Institutional Equity Comparison Engine

ENTX vs IBO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

IBO Overall Edge

IBO Captures Institutional Edge (3โ€“1 Pillars ยท 5โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Impact BioMedical, Inc. (IBO) driven by superior Valuation, Growth & Margin, Momentum & Technical while ENTX counters with relative strength in Options & Structure. Fundamentally, ENTX trades at N/M Forward P/E with 0.0% operating margin (-100.0% YoY revenue) versus IBO at N/M Forward P/E and -12621.0% operating margin (+16.7% YoY). In options structure, ENTX sits in CONSOLIDATION (32nd %ile IV; Dealer Gamma Walls on Pro) against IBO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner IBO
ENTX N/M vs IBO N/M Fwd P/E
Growth & Margin Winner IBO
Op Margin 0.0% vs -12621.0% ยท YoY -100.0% vs +16.7%
Momentum & Technical Winner IBO
1Y +10.2% vs +862.8% ยท 52W Pos 64% vs 67%
Options & Structure Winner ENTX
CONSOLIDATION (32nd %ile IV) vs UNCLASSIFIED (N/A IV)
ENTX NASDAQ
Entera Bio Ltd. Ordinary Shares
Biological Products, (No Disgnostic Substances)
$3.02
-2.89% 1D
Market Cap $541.6M
1M Return +12.69%
1Y Return +10.22%
Forward P/E N/M
Unified AI Score
48.1 / 100 HOLD
Tech 34.0 Fund 51.0 Flow 76.0 Mom 60.0
IBO NYSE American
Impact BioMedical, Inc.
Pharmaceutical Preparations
$4.91
-4.47% 1D
Market Cap $44.4M
1M Return +83.21%
1Y Return +862.75%
Forward P/E N/M
Unified AI Score
36.8 / 100 SELL
Tech 15.0 Fund 32.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ENTX +10.22% IBO +862.75% Spread: +852.53 pp (IBO Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period ENTX Revenue IBO Revenue ENTX Op. Margin IBO Op. Margin Margin Edge
FY2020 $0M N/A -3059.7% N/A ENTX
FY2021 $0M N/A -2139.6% N/A ENTX
FY2022 $0M $0M -9714.2% -6808.0% IBO
FY2024 $0M N/A -5295.6% N/A ENTX
FY2025 $0M $0M -27450.0% -13381.2% IBO

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ENTX (4) vs IBO (5)
Institutional Metric ENTX IBO Criterion Row Winner
Market Capitalization Scale $541.6M $44.4M Larger Scale ENTX
Trailing P/E Ratio Valuation N/M 0.4x Lower Multiple IBO
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +16.7% Higher Growth IBO
Operating Margin (TTM) Profitability 0.0% -12621.0% Higher Margin ENTX
Net Profit Margin Profitability 0.0% 4247.4% Higher Margin IBO
Return on Equity (ROE) Capital Efficiency -20.3% 71.2% Higher ROE IBO
52-Week Range Position Momentum 64% ($1โ€“$4) 67% ($0โ€“$7) Stronger Trend IBO
Beta / 30D Volatility Risk Regime 1.07ฮฒ ยท 46% Vol -6.72ฮฒ ยท 120% Vol Lower Realized Risk ENTX
Unified Institutional Score Composite Signal 48.1 / 100 (HOLD) 36.8 / 100 (SELL) Higher Composite ENTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ENTX vs IBO Buy Guide
ENTX CONSOLIDATION
79d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 32nd %ile
IV Regime Balanced (25thโ€“60th %ile)
Live ENTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IBO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live IBO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ENTX nor IBO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.